×

Nucleotide sequence and pharmaceutical composition based thereon with prolonged VEGF transgene expression

  • US 10,040,837 B2
  • Filed: 11/21/2017
  • Issued: 08/07/2018
  • Est. Priority Date: 05/26/2015
  • Status: Active Grant
First Claim
Patent Images

1. A method for extending the lifetime of mRNA encoding vascular endothelial growth factor (VEGF) in a host cell comprising:

  • performing at least one modification selected from the group consisting of at least one pointwise single deletion of guanine, adenosine, thiamine, or cytosine, and at least one pointwise single substitution of guanine or adenosine with cytosine, in the 3′

    -untranslated region of a VEGF gene to produce at least one engineered polynucleotide;

    transforming the at least one engineered polynucleotide into a host cell,determining lifetime of said at least one mutant mRNA in the host cell, wherein when the engineered polynucleotide is transformed into and transcribed by the host cell, the at least one mutant mRNA is its transcription product, andselecting at least one mutant mRNA that has an extended lifetime compared to lifetime of an otherwise identical control mRNA which is a transcription product of the VEGF gene that has not been mutated.

View all claims
  • 0 Assignments
Timeline View
Assignment View
    ×
    ×